ArticleNeuro-oncology2007
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
Article in Neuro-oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 122 citations in OpenAlex.
- Locoregional Delivery of miRNAs for Glioblastoma Treatment: A Systematic Review of Advances in Delivery Systems.Pharmaceutics · 2026Review
- Brain neurovascular unit in response to intra- and extra-central nervous system cancers: implications, mechanisms, and challenges.Cancer cell international · 2025Review
- A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.Journal of neuro-oncology · 2025Article
- Layer-by-Layer Polymer Functionalization Improves Nanoparticle Penetration and Glioblastoma Targeting in the Brain.ACS nano · 2023Article
- Ultrasound-mediated delivery of flexibility-tunable polymer drug conjugates for treating glioblastoma.Bioengineering & translational medicine · 2023Article
- Article
- Hyaluronic acid conjugates for topical treatment of skin cancer lesions.Science advances · 2021Article
- Blood-Brain Barrier Modulation to Improve Glioma Drug Delivery.Pharmaceutics · 2020Review
- Article
- Treatment of glioblastoma using multicomponent silica nanoparticles.Advanced therapeutics · 2019Article
- Article
- Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment.Current neuropharmacology · 2017Article
- Targeted Nanotechnology in Glioblastoma Multiforme.Frontiers in pharmacology · 2017Review
- Crossing the barrier: treatment of brain tumors using nanochain particles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy.Theranostics · 2016Article
- Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Therapeutic delivery · 2015Review
- Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration.ACS nano · 2014Article
- Multifunctional nanoparticles for brain tumor imaging and therapy.Advanced drug delivery reviews · 2014Review
- Nanoscale drug delivery systems and the blood-brain barrier.International journal of nanomedicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously shown that convection-enhanced delivery (CED) of highly stable nanoparticle/liposome agents encapsulating chemotherapeutic drugs is effective against intracranial rodent brain tumor xenografts. In this study, we have evaluated the combination of a newly developed nanoparticle/liposome containing the topoisomerase I inhibitor CPT-11 (nanoliposomal CPT-11 [nLs-CPT-11]), and PEGylated liposomal doxorubicin (Doxil) containing the topoisomerase II inhibitor doxorubicin. Both drugs were detectable in the CNS for more than 36 days after a single CED application. Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil. The combination of the two agents produced synergistic cytotoxicity in vitro. In vivo in U251MG and U87MG intracranial rodent xenograft models, CED of the combination was also more efficacious than either agent used singly. Analysis of the parameters involved in this approach indicated that tissue pharmacokinetics, tumor microanatomy, and biochemical interactions of the drugs all contributed to the therapeutic efficacy observed. These findings have implications for further clinical applications of CED-based treatment of brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.